Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

Yetrib Hathout, Edward Brody, Paula R. Clemens, Linda Cripe, Robert Kirk DeLisle, Pat Furlong, Heather Gordish-Dressman, Lauren Hache, Erik K Henricson, Eric P. Hoffman, Yvonne Monique Kobayashi, Angela Lorts, Jean K. Mah, Craig M McDonald, Bob Mehler, Sally Nelson, Malti Nikrad, Britta Singer, Fintan Steele, David SterlingH. Lee Sweeney, Steve Williams, Larry Gold

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and agematched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy-Cincinnati Children's Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1% false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.

Original languageEnglish (US)
Pages (from-to)7153-7158
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume112
Issue number23
DOIs
StatePublished - Jun 9 2015

Fingerprint

Duchenne Muscular Dystrophy
Blood Proteins
Biomarkers
Healthy Volunteers
Proteins
Serum
Muscular Dystrophies
Rare Diseases
Natural History
Proteomics
Outcome Assessment (Health Care)
Technology
Therapeutics
Research
Pharmaceutical Preparations

Keywords

  • Biomarkers
  • Muscular dystrophy
  • Proteomics
  • SOMAmer
  • SOMAscan

ASJC Scopus subject areas

  • General

Cite this

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. / Hathout, Yetrib; Brody, Edward; Clemens, Paula R.; Cripe, Linda; DeLisle, Robert Kirk; Furlong, Pat; Gordish-Dressman, Heather; Hache, Lauren; Henricson, Erik K; Hoffman, Eric P.; Kobayashi, Yvonne Monique; Lorts, Angela; Mah, Jean K.; McDonald, Craig M; Mehler, Bob; Nelson, Sally; Nikrad, Malti; Singer, Britta; Steele, Fintan; Sterling, David; Sweeney, H. Lee; Williams, Steve; Gold, Larry.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 23, 09.06.2015, p. 7153-7158.

Research output: Contribution to journalArticle

Hathout, Y, Brody, E, Clemens, PR, Cripe, L, DeLisle, RK, Furlong, P, Gordish-Dressman, H, Hache, L, Henricson, EK, Hoffman, EP, Kobayashi, YM, Lorts, A, Mah, JK, McDonald, CM, Mehler, B, Nelson, S, Nikrad, M, Singer, B, Steele, F, Sterling, D, Sweeney, HL, Williams, S & Gold, L 2015, 'Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy', Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 23, pp. 7153-7158. https://doi.org/10.1073/pnas.1507719112
Hathout, Yetrib ; Brody, Edward ; Clemens, Paula R. ; Cripe, Linda ; DeLisle, Robert Kirk ; Furlong, Pat ; Gordish-Dressman, Heather ; Hache, Lauren ; Henricson, Erik K ; Hoffman, Eric P. ; Kobayashi, Yvonne Monique ; Lorts, Angela ; Mah, Jean K. ; McDonald, Craig M ; Mehler, Bob ; Nelson, Sally ; Nikrad, Malti ; Singer, Britta ; Steele, Fintan ; Sterling, David ; Sweeney, H. Lee ; Williams, Steve ; Gold, Larry. / Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. In: Proceedings of the National Academy of Sciences of the United States of America. 2015 ; Vol. 112, No. 23. pp. 7153-7158.
@article{06bd2d0ab2da4d5a94c4d6f751bfceca,
title = "Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy",
abstract = "Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and agematched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy-Cincinnati Children's Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1{\%} false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.",
keywords = "Biomarkers, Muscular dystrophy, Proteomics, SOMAmer, SOMAscan",
author = "Yetrib Hathout and Edward Brody and Clemens, {Paula R.} and Linda Cripe and DeLisle, {Robert Kirk} and Pat Furlong and Heather Gordish-Dressman and Lauren Hache and Henricson, {Erik K} and Hoffman, {Eric P.} and Kobayashi, {Yvonne Monique} and Angela Lorts and Mah, {Jean K.} and McDonald, {Craig M} and Bob Mehler and Sally Nelson and Malti Nikrad and Britta Singer and Fintan Steele and David Sterling and Sweeney, {H. Lee} and Steve Williams and Larry Gold",
year = "2015",
month = "6",
day = "9",
doi = "10.1073/pnas.1507719112",
language = "English (US)",
volume = "112",
pages = "7153--7158",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "23",

}

TY - JOUR

T1 - Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy

AU - Hathout, Yetrib

AU - Brody, Edward

AU - Clemens, Paula R.

AU - Cripe, Linda

AU - DeLisle, Robert Kirk

AU - Furlong, Pat

AU - Gordish-Dressman, Heather

AU - Hache, Lauren

AU - Henricson, Erik K

AU - Hoffman, Eric P.

AU - Kobayashi, Yvonne Monique

AU - Lorts, Angela

AU - Mah, Jean K.

AU - McDonald, Craig M

AU - Mehler, Bob

AU - Nelson, Sally

AU - Nikrad, Malti

AU - Singer, Britta

AU - Steele, Fintan

AU - Sterling, David

AU - Sweeney, H. Lee

AU - Williams, Steve

AU - Gold, Larry

PY - 2015/6/9

Y1 - 2015/6/9

N2 - Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and agematched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy-Cincinnati Children's Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1% false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.

AB - Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs of drug effects, and be useful as surrogate outcome measures to predict later clinical benefit. In this study a large-scale biomarker discovery was performed on serum samples from patients with DMD and agematched healthy volunteers using a modified aptamer-based proteomics technology. Levels of 1,125 proteins were quantified in serum samples from two independent DMD cohorts: cohort 1 (The Parent Project Muscular Dystrophy-Cincinnati Children's Hospital Medical Center), 42 patients with DMD and 28 age-matched normal volunteers; and cohort 2 (The Cooperative International Neuromuscular Research Group, Duchenne Natural History Study), 51 patients with DMD and 17 age-matched normal volunteers. Forty-four proteins showed significant differences that were consistent in both cohorts when comparing DMD patients and healthy volunteers at a 1% false-discovery rate, a large number of significant protein changes for such a small study. These biomarkers can be classified by known cellular processes and by age-dependent changes in protein concentration. Our findings demonstrate both the utility of this unbiased biomarker discovery approach and suggest potential new diagnostic and therapeutic avenues for ameliorating the burden of DMD and, we hope, other rare and devastating diseases.

KW - Biomarkers

KW - Muscular dystrophy

KW - Proteomics

KW - SOMAmer

KW - SOMAscan

UR - http://www.scopus.com/inward/record.url?scp=84931281834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931281834&partnerID=8YFLogxK

U2 - 10.1073/pnas.1507719112

DO - 10.1073/pnas.1507719112

M3 - Article

C2 - 26039989

AN - SCOPUS:84931281834

VL - 112

SP - 7153

EP - 7158

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 23

ER -